TARS insider filings

Tarsus Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-17. Screen TARS transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 11 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Azamian Bobak R. — President/CEO and Board Chair, Director3—4 legs · 30,000 sh · $2,509,300—
Lin Elizabeth Yeu — Chief Medical Officer2—7 legs · 25,531 sh · $2,118,875—
LINK WILLIAM J PHD — Director1—3 legs · 12,500 sh · $979,7442
Neervannan Seshadri — Chief Operating Officer1—1 leg · 4,564 sh · $387,940—
Clase Neera — Chief Commercial Officer2——2
PYOTT DAVID E I — Director1——2
YARNO WENDY L — Director1——2

Recent insider filings — Tarsus Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2026-11-174Azamian Bobak R. — President/CEO and Board Chair, DirectorSale (S): 10,000 @ $80.31EDGAR
2026-11-053Clase Neera — Chief Commercial OfficerHoldings only — no transactions reportedEDGAR
2026-11-054Clase Neera — Chief Commercial OfficerGrant/award (A): 10,587 (derivative) @ $0 · Grant/award (A): 6,678 (derivative) @ $0EDGAR
2026-09-174PYOTT DAVID E I — DirectorOption exercise (M): 201 · Option exercise (M): 201 (derivative) @ $0EDGAR
2026-09-174LINK WILLIAM J PHD — DirectorOption exercise (M): 201 · Sale (S): 11,675 @ $78.33 · Sale (S): 759 @ $79 · Sale (S): 66 @ $80.01 · Option exercise (M): 201 (derivative) @ $0EDGAR
2026-09-174YARNO WENDY L — DirectorOption exercise (M): 302 · Option exercise (M): 302 (derivative) @ $0EDGAR
2026-09-094Azamian Bobak R. — President/CEO and Board Chair, DirectorSale (S): 7,100 @ $90.27 · Sale (S): 2,900 @ $91.27EDGAR
2026-09-094Neervannan Seshadri — Chief Operating OfficerSale (S): 4,564 @ $85EDGAR
2026-09-094Lin Elizabeth Yeu — Chief Medical OfficerSale (S): 5,387 @ $85 · Sale (S): 5,386 @ $90 · Sale (S): 1,590 @ $85 · Sale (S): 1,590 @ $90EDGAR
2026-09-034Lin Elizabeth Yeu — Chief Medical OfficerSale (S): 4,601 @ $73.86 · Sale (S): 5,387 @ $80 · Sale (S): 1,590 @ $80EDGAR
2026-09-034Azamian Bobak R. — President/CEO and Board Chair, DirectorSale (S): 10,000 @ $80.06EDGAR
2026-06-294Goodrich Katherine — DirectorGrant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0EDGAR
2026-06-294Goldberg Andrew D. — DirectorGrant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0EDGAR
2026-06-294Morrison Scott W — DirectorGrant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0EDGAR
2026-06-294CHAUDHURI BHASKAR — DirectorGrant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0EDGAR
2026-06-294LINK WILLIAM J PHD — DirectorGrant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 806 (derivative) @ $0EDGAR
2026-06-294YARNO WENDY L — DirectorGrant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 1,209 (derivative) @ $0EDGAR
2026-06-294PYOTT DAVID E I — DirectorGrant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 806 (derivative) @ $0EDGAR
2026-06-224Azamian Bobak R. — President/CEO and Board Chair, DirectorSale (S): 4,582 @ $61.24 · Sale (S): 5,418 @ $61.81EDGAR
2026-06-174Goodrich Katherine — DirectorSale (S): 2,954 @ $62.08EDGAR
2026-06-174Farrow Jeffrey S — See RemarksOption exercise (M): 27,881 · Sale (S): 14,396 @ $60.95 · Option exercise (M): 27,881 (derivative) @ $0EDGAR
2026-06-174LINK WILLIAM J PHD — DirectorSale (S): 10,572 @ $61.97 · Sale (S): 1,928 @ $62.94EDGAR
2026-06-164Goodrich Katherine — DirectorOption exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0EDGAR
2026-06-164Goldberg Andrew D. — DirectorOption exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0EDGAR
2026-06-164Morrison Scott W — DirectorOption exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0EDGAR
2026-06-164CHAUDHURI BHASKAR — DirectorOption exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0EDGAR
2026-06-164LINK WILLIAM J PHD — DirectorOption exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0EDGAR
2026-06-164YARNO WENDY L — DirectorOption exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0EDGAR
2026-04-284PYOTT DAVID E I — DirectorOption exercise (M): 1,383 · Option exercise (M): 1,383 (derivative) @ $0EDGAR
2026-03-244Neervannan Seshadri — Chief Operating OfficerSale (S): 2,989 @ $66.75EDGAR
2026-03-194Lin Elizabeth Yeu — Chief Medical OfficerSale (S): 375 @ $69.42 · Sale (S): 379 @ $68.71 · Sale (S): 390 @ $67EDGAR
2026-03-194Wahl Bryan — General CounselSale (S): 4,084 @ $69.42 · Sale (S): 4,125 @ $68.71 · Sale (S): 4,231 @ $67EDGAR
2026-03-194Whitfield Dianne C. — Chief Human Resources OfficerSale (S): 4,029 @ $69.42 · Sale (S): 4,071 @ $68.71 · Sale (S): 4,174 @ $67EDGAR
2026-03-194Azamian Bobak R. — President/CEO and Board Chair, DirectorSale (S): 10,972 @ $69.42 · Sale (S): 11,667 @ $68.71 · Sale (S): 11,964 @ $67EDGAR
2026-03-194Neervannan Seshadri — Chief Operating OfficerSale (S): 3,125 @ $69.42 · Sale (S): 3,610 @ $68.71 · Sale (S): 4,589 @ $67EDGAR
2026-03-194Mottiwala Aziz — Chief Commercial OfficerSale (S): 4,286 @ $69.42 · Sale (S): 4,330 @ $68.71 · Sale (S): 4,440 @ $67EDGAR
2026-03-194Farrow Jeffrey S — See RemarksSale (S): 2,111 @ $69.42 · Sale (S): 2,133 @ $68.71 · Sale (S): 2,186 @ $67EDGAR
2026-03-184LINK WILLIAM J PHD — DirectorSale (S): 3,629 @ $68.09 · Sale (S): 8,378 @ $69.03 · Sale (S): 493 @ $69.75EDGAR
2026-03-174Lin Elizabeth Yeu — Chief Medical OfficerOption exercise (M): 2,511 · Option exercise (M): 2,511 (derivative) @ $0EDGAR
2026-03-174Wahl Bryan — General CounselOption exercise (M): 24,236 · Option exercise (M): 4,790 (derivative) @ $0 · Option exercise (M): 7,248 (derivative) @ $0 · Option exercise (M): 7,176 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0EDGAR
2026-03-174Whitfield Dianne C. — Chief Human Resources OfficerOption exercise (M): 23,909 · Option exercise (M): 4,463 (derivative) @ $0 · Option exercise (M): 7,248 (derivative) @ $0 · Option exercise (M): 7,176 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0EDGAR
2026-03-174Azamian Bobak R. — President/CEO and Board Chair, DirectorOption exercise (M): 66,274 · Option exercise (M): 11,300 (derivative) @ $0 · Option exercise (M): 16,975 (derivative) @ $0 · Option exercise (M): 23,121 (derivative) @ $0 · Option exercise (M): 14,878 (derivative) @ $0EDGAR
2026-03-174Neervannan Seshadri — Chief Operating OfficerOption exercise (M): 26,287 · Option exercise (M): 5,097 (derivative) @ $0 · Option exercise (M): 8,148 (derivative) @ $0 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0EDGAR
2026-03-174Mottiwala Aziz — Chief Commercial OfficerOption exercise (M): 26,482 · Option exercise (M): 4,790 (derivative) @ $0 · Option exercise (M): 8,148 (derivative) @ $0 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,524 (derivative) @ $0EDGAR
2026-03-174Farrow Jeffrey S — See RemarksOption exercise (M): 13,042 · Option exercise (M): 8,020 (derivative) @ $0 · Option exercise (M): 5,022 (derivative) @ $0EDGAR
2026-03-094Whitfield Dianne C. — Chief Human Resources OfficerGrant/award (A): 27,310 (derivative) @ $0 · Grant/award (A): 17,161 (derivative) @ $0EDGAR
2026-03-094Azamian Bobak R. — President/CEO and Board Chair, DirectorGrant/award (A): 96,723 (derivative) @ $0 · Grant/award (A): 60,776 (derivative) @ $0EDGAR
2026-03-094Neervannan Seshadri — Chief Operating OfficerGrant/award (A): 27,310 (derivative) @ $0 · Grant/award (A): 17,161 (derivative) @ $0EDGAR
2026-03-094Mottiwala Aziz — Chief Commercial OfficerGrant/award (A): 30,724 (derivative) @ $0 · Grant/award (A): 19,306 (derivative) @ $0EDGAR
2026-03-094Farrow Jeffrey S — See RemarksGrant/award (A): 30,724 (derivative) @ $0 · Grant/award (A): 19,306 (derivative) @ $0EDGAR

Recent 8-K events — Tarsus Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-038-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-138-K/A9.01 — Financial Statements and ExhibitsEDGAR
2026-09-108-K2.01 — Completion of Acquisition or Disposition of Assets
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-138-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-07-088-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-298-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TARS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs